Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

4.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.4K
Clinical Trials01:16

Clinical Trials

10.0K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.0K
Preclinical Development: Overview01:28

Preclinical Development: Overview

5.6K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.6K
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

101
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
101
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.6K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nirmatrelvir-ritonavir versus usual care in at-risk adults with early SARS-CoV-2 infection in the UK, 2022-23: virological and immunological results of an open-label randomised trial (PANORAMIC).

The Lancet. Microbe·2026
Same author

Oral Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk Outpatients.

The New England journal of medicine·2026
Same author

Early Versus Delayed Anticoagulation in Acute Ischemic Stroke According to Atrial Fibrillation Subtype and Time of Diagnosis: Subgroup Analysis of the OPTIMAS Randomized Controlled Trial.

Stroke·2026
Same author

Population pharmacokinetic/pharmacodynamic modelling to evaluate favipiravir in combination with lopinavir-ritonavir in patients with COVID-19.

British journal of clinical pharmacology·2026
Same author

Risk factors and surrogate indicators for cardiovascular disease are prevalent in Common Variable Immunodeficiency and associate with inflammatory phenotype.

Frontiers in immunology·2026
Same author

Extensive evolution and T cell escape by SARS-CoV-2 in a 2.5-year persistent infection of an immunocompromised host.

iScience·2026
Same journal

Predictor-Assisted Nonparametric Graphical Models With Multivariate Error-Prone Data.

Statistics in medicine·2026
Same journal

Optimizing Treatment Decision Estimation for Right-Censored Survival Data Through Parameter Transfer Learning.

Statistics in medicine·2026
Same journal

Latent Class Log-Linear Models for Estimating Diagnostic Test Accuracy Without a Gold Standard: A Simulation Study.

Statistics in medicine·2026
Same journal

Interpretable Bayesian Modeling for Multireader Multicase Studies: Addressing Overdispersion and Limited Sample Size in Diagnostic Enhancement Evaluation.

Statistics in medicine·2026
Same journal

Adaptive Sequential Multiple Hypotheses Testing for Concomitant Vaccine Safety Surveillance.

Statistics in medicine·2026
Same journal

Novel Distance Regression for Repeated Outcomes With Missing Data: Applications to Longitudinal and Crossover Studies of Microbiome Beta-Diversity.

Statistics in medicine·2026
See all related articles

Related Experiment Video

Updated: Dec 5, 2025

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

30.7K

Early phase dose-finding trials in virology.

Hakim-Moulay Dehbi1, David M Lowe2, John O'Quigley3

  • 1Comprehensive Clinical Trials Unit, University College London, London, UK.

Statistics in Medicine
|October 14, 2020
PubMed
Summary
This summary is machine-generated.

This study introduces novel dose-finding methods for antiviral therapies, focusing on optimizing treatment outcomes and patient benefits in virology. The approach addresses unique challenges in antiviral drug development beyond traditional oncology models.

Keywords:
continual reassessment methodcoronavirusdose-findingearly phase trialsnorovirusvirology

More Related Videos

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses
11:34

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses

Published on: May 5, 2014

14.2K
Assays for the Identification of Novel Antivirals against Bluetongue Virus
12:02

Assays for the Identification of Novel Antivirals against Bluetongue Virus

Published on: October 11, 2013

14.4K

Related Experiment Videos

Last Updated: Dec 5, 2025

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

30.7K
High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses
11:34

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses

Published on: May 5, 2014

14.2K
Assays for the Identification of Novel Antivirals against Bluetongue Virus
12:02

Assays for the Identification of Novel Antivirals against Bluetongue Virus

Published on: October 11, 2013

14.4K

Area of Science:

  • Virology
  • Pharmacology
  • Clinical Trial Design

Background:

  • Dose-finding methodology has significantly advanced in oncology but remains underexplored in virology.
  • Antiviral drug development faces unique challenges, including treatment cessation due to side effects and a spectrum of treatment success beyond binary outcomes.

Purpose of the Study:

  • To propose a novel dose-finding methodology tailored for antiviral therapies.
  • To identify optimal antiviral drug doses that yield the most favorable distribution of treatment outcomes.
  • To maximize treatment benefits for patients participating in clinical trials.

Main Methods:

  • Development of a new statistical framework for dose-finding in virology.
  • Focus on a spectrum of treatment responses, from partial viral load reduction to complete viral elimination.
  • Incorporation of patient benefit maximization within the dose-finding process.

Main Results:

  • The proposed methodology aims to identify doses providing the best outcome distributions.
  • It seeks to enhance patient benefit by optimizing dose selection.
  • This approach is motivated by an upcoming trial for chronic norovirus infection.

Conclusions:

  • Novel dose-finding methods are crucial for advancing antiviral drug development.
  • The proposed methodology offers a framework to address the complexities of antiviral treatment response.
  • This work has the potential to improve clinical trial design and patient outcomes in virology.